Hellenic Cooperative Oncology Group

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

Retrospective Consortium Analysis, Medicine, Pathology +5

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

Kathleen N. Moore, Michael A. Bookman, Jalid Sehouli et al. · Journal of Clinical Oncology · 2021 · 376 citations · Full text

CircNT5E Acts as a Sponge of miR-422a to Promote Glioblastoma Tumorigenesis

Renjie Wang, Sai Zhang, Xuyi Chen et al. · Cancer Research · 2018 · 334 citations

Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer

D. Skarlos, E. Samantas, P. Kosmidis et al. · Annals of Oncology · 1994 · 274 citations · Full text

Radiation Medicine, Health Sciences, Radiation Therapy +8

Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: a randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation

George Fountzilas, E. Ciuleanu, Mattheos Bobos et al. · Annals of Oncology · 2011 · 247 citations · Full text

Weekly Cisplatin, Radiation Therapy, Same Concomitant Chemoradiotherapy +8